Edition:
United Kingdom

Allakos Inc (ALLK.OQ)

ALLK.OQ on NASDAQ Stock Exchange Global Select Market

62.63USD
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
$62.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,603
52-wk High
$63.03
52-wk Low
$26.00

Summary

Name Age Since Current Position

Daniel Janney

52 2017 Chair of the Board

Robert Alexander

48 2017 President, Chief Executive Officer, Director

Nenad Tomasevic

2016 Co-Founder, Vice President - Research

Adam Tomasi

48 2017 Chief Financial Officer, Chief Operating Officer, Secretary

Sally Bolmer

Vice President - Regulatory Affairs and Drug Development

Ruby Casareno

Vice President - Manufacturing

Mark Asbury

2018 Chief Legal Officer and General Counsel

Simon Greenwood

Chief Business Officer

Henrik Rasmussen

59 2017 Chief Medical Officer

Tim Varacek

Chief Commercial Officer

Robert Andreatta

56 2018 Independent Director

Steven James

60 2016 Independent Director

John McKearn

64 2012 Independent Director

Paul Walker

43 2017 Independent Director

Biographies

Name Description

Daniel Janney

Mr. Daniel (Dan) S. Janney is Chair of the Board of the company. He has served as a member of our board of directors since March 2017 and as Chair of our board of directors since June 2017. Mr. Janney is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996, Mr. Janney was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a number of companies including Esperion Therapeutics, Evolve Biosystems, Krystal Biotech, Prolacta Bioscience, Sutro Biopharma and Viveve Medical. Mr. Janney is currently a member of the California Academy of Sciences Board of Trustees. He holds a Bachelor of Arts in history from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Robert Alexander

Dr. Robert D. Alexander Ph.D., is President, Chief Executive Officer, Director of the Company. He has served as a member of our Board of Directors since May 2017, as our Chief Executive Officer since April 2017 and as our President since November 29, 2017. He previously served as a member of our Board of Directors from December 2012 until June 2013. From December 2013 to April 2017, Dr. Alexander served as Chief Executive Officer of ZS Pharma (acquired by AstraZeneca in December 2015), where he also served as a member of the board of directors, including as Chairman from March 2013 to March 2014. From November 2005 to March 2013, Dr. Alexander served as a Director at Alta Partners, a venture capital firm in life sciences. In addition, he acted as Executive Chairman and interim Chief Executive Officer of SARcode Biosciences (acquired by Shire plc in April 2013), a biopharmaceutical company. During his time at Alta, he led investments in SARcode Biosciences, Lumena Pharmaceuticals, ZS Pharma and Allakos. Previously, Dr. Alexander was a Principal in MPM Capital’s BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments. Dr. Alexander also previously worked in the Business Development group at Genentech (now a member of the Roche Group), a biotechnology company, where he was responsible for sourcing and screening product opportunities based on scientific merit and strategic fit, leading diligence teams and negotiating terms and definitive agreements. He is currently a director at Allena Pharmaceuticals. Dr. Alexander joined Genentech after completing his post-doctoral fellowship at Stanford University in the Pathology department. He also holds a Ph.D. with a focus in immunology from the University of North Carolina and a B.A. in zoology from Miami University of Ohio.

Nenad Tomasevic

Dr. Nenad Tomasevic, Ph.D., is Co-Founder, Vice President - Research of the Company. Dr. Tomasevic co-founded Allakos in 2012. Prior to Allakos, Dr. Tomasevic was Director of Protein Biochemistry at KaloBios where his team supported preclinical and clinical activities for three clinical-stage antibodies. Dr. Tomasevic has also held positions at Nuvelo, where he led a protein biochemistry group, and at Cytokinetics where he led a team that identified small molecule inhibitors cell motility proteins. Dr. Tomasevic received a Bachelor of Science in Chemistry, a Master of Science and PhD in Biochemistry from the University of Belgrade in Yugoslavia. He completed postdoctoral training at National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland in the laboratory of Dr. Brenda Peculis. During this time, he discovered two previously uncharacterized proteins.

Adam Tomasi

Dr. Adam Tomasi, Ph.D. is Chief Financial Officer, Chief Operating Officer, Secretary of the Company. He has served as our Chief Operating Officer and Chief Financial Officer since April 2017 and as Secretary since November 2017. From August 2013 to January 2015, Dr. Tomasi served as Senior Vice President, Corporate Development of ZS Pharma, and from February 2015 to March 2017, he served as Chief Scientific Officer and Head of Corporate Development of ZS Pharma. Previously, Dr. Tomasi was a Principal at Alta Partners, where he was involved in the funding and development of notable medical technology and life science companies including Chemgenex, Excaliard, Lumena Pharmaceuticals, Achaogen, Immune Design, Allakos and ZS Pharma. Prior to joining Alta Partners, Dr. Tomasi was in the Harvard-MIT Biomedical Enterprise Program where he completed internships as an equity analyst at Lehman Brothers and at MPM Capital. Dr. Tomasi also previously worked as a medicinal chemist with Gilead Sciences and Cytokinetics, where he helped create the cardiovascular drug CK-1827452, which was licensed to Amgen. Dr. Tomasi holds a B.S. in Chemistry from the University of California, Berkeley, an MBA from the Massachusetts Institute of Technology Sloan School of Management and a Ph.D. in Chemistry from the University of California, Irvine.

Sally Bolmer

Dr. Sally D. Bolmer Ph.D. RAC is Vice President - Regulatory Affairs and Drug Development of the Company. Dr. Bolmer has more than 25 years of experience in the biopharmaceutical industry. She was the Senior Vice President of Development and Regulatory Affairs at Human Genome Sciences with responsibility for formulation and implementation of global regulatory and drug development strategies. Prior to Human Genome Sciences, Dr. Bolmer held various scientific and leadership roles at Centocor including Executive Director for Regulatory Affairs. While at Centocor, she was responsible for preclinical, clinical and manufacturing strategy and submissions for INDs and Marketing Applications for Cardiovascular, Immunology, Oncology and Infectious disease products. During her career, she has secured approval for five first-in-class biologics, initiated INDs for over 50 indications, and submitted over 6 BLAs for products including murine, chimeric and human antibodies; radioconjugates; antibody fragments; and fusion proteins. Dr. Bolmer received a Bachelor of Science in Biochemistry from Brown University and a PhD in Biological Chemistry from the Hershey Medical Center of Penn State University. She had a post-doctorate appointment at MIT in the Applied Biological Science and was an Assistant Research Professor at Mt. Sinai Medical Center in New York City studying glycoprotein synthesis.

Ruby Casareno

Dr. Ruby Casareno, Ph.D. is Vice President - Manufacturing of the Company. Dr. Casareno has more than 17 years of biopharmaceutical experience in biologics process development, scale up, technology transfer, and contract manufacturing oversight. She contributed to 3 commercial and over 18 pre-clinical and clinical development programs. She was Director, Outsourced Manufacturing & Manufacturing Sciences and Technology at Portola Pharmaceuticals and led the biologics team in addressing BLA drug substance manufacturing-related regulatory questions. As Director of Process Development and Manufacturing at Oncomed Pharmaceuticals, she was responsible for biologics process development and ensuring GMP adherence for 9 clinical development programs. She held various scientific and leadership positions at Seattle Genetics, Maxygen, Johnson and Johnson (Scios), Xoma and Bio-Rad Laboratories. Dr. Casareno has a Bachelor of Science in Chemistry from the University of the Philippines and received her PhD in Chemistry from The Ohio State University. She completed postdoctoral trainings at Washington University Medical School and at the University of California, San Francisco.

Mark Asbury

Mr. Mark A. Asbury is Chief Legal Officer and General Counsel of the Company since November 2018. He has more than 20 years in the pharmaceutical industry at various size companies. Since 2016, Mr. Asbury was General Counsel at Samsara BioCapital, a science-driven venture capital firm. From 2014 to 2016 Mr. Asbury was Chief Legal Officer and General Counsel at ZS Pharma (acquired by AstraZeneca) where he was responsible for all legal aspects of the organization, including intellectual property, SEC matters and strategic transactions. Prior to ZS Pharma, he was the Vice President and General Counsel of Pharmacyclics where he helped the company negotiate a $975 million deal with Johnson & Johnson for ibrutinib, its Phase 2 molecule. Prior to that, Mr. Asbury held a variety of positions at Genentech, most recently as Associate General Counsel and Senior Director of Transactional Law. Prior to joining Genentech, he worked for the law firm of Shearman & Sterling, where he specialized in corporate finance, mergers and acquisitions, and commercial debt financings. Mr. Asbury has a BA in Soviet studies from Vanderbilt University and a JD from Stanford Law School.

Simon Greenwood

Dr. Simon Greenwood, Ph.D. is Chief Business Officer of the Company. Dr. Greenwood has over 20 years of experience in the healthcare industry. Prior to joining Allakos, Dr. Greenwood was Investment Director for the Roche Venture Fund, where he led investments in 23andMe, Allakos, Biodesy, CytomX (NASDQ: CYMX), DVS (acquired by Fluidigm), Epic Sciences, Horizon Discovery (AIM: HZD), Maculogix, ProActa and Stratos. Prior to his role at the Roche Venture Fund, Dr. Greenwood was the head of GenenFund, Genentech’s corporate venture fund, and he also held roles in research and business development at Genentech. Dr. Greenwood holds a PhD in Genetics and Development from Columbia University College of Physicians and Surgeons, where he was a Fulbright Scholar.

Henrik Rasmussen

Dr. Henrik Sandvad Rasmussen M.D., Ph.D. is Chief Medical Officer of the Company since June 2017. From October 2012 through June 2016, Dr. Rasmussen served as Chief Medical Officer at ZS Pharma, a biotechnology company. From August 2009 to October 2012 and from June 2015 to June 2017, Dr. Rasmussen served as President and Chief Executive Officer of Rasmussen Biotech and Pharma Consulting. Dr. Rasmussen also previously held the positions of Corporate Vice President and Head of Clinical Development and Medical and Regulatory Affairs at Novo Nordisk. He also previously served as Chief Medical Officer for Nabi Biopharmaceuticals and Genvec. He was also previously Vice President for Clinical Research and Senior Vice President for Clinical Research and Regulatory Affairs at British Biotech and International Clinical Project Manager and Global Study Director for cardiovascular drug development at Pfizer Central Research. Dr. Rasmussen has led numerous global development programs and regulatory filings worldwide, including NDAs. Dr. Rasmussen received his M.D. and Ph.D. from the University of Copenhagen in Denmark and is trained in internal medicine and cardiology.

Tim Varacek

Mr. Tim Varacek is Chief Commercial Officer of the Company. Mr. Varacek has 30 years of experience in biopharmaceutical sales, account management, marketing and commercial operations leadership. Most recently, Mr. Varacek was the Senior Vice President, Sales and Commercial Operations at ZS Pharma (acquired by AstraZeneca). Prior to ZS Pharma, he held a variety of executive and management-level roles at InterMune (acquired by Roche AG), Affymax, Amgen and BMS. In his commercial leadership roles, Mr. Varacek has launch expertise with specialty, non-specialty, orphan disease products including both biologics and small molecule compounds. Mr. Varacek has a Bachelor of Science in Biology from SUNY Binghamton.

Robert Andreatta

Mr. Robert E. Andreatta is an Independent Director of the Company since June 2018. Mr. Andreatta has served as Vice President, Controller at Google LLC since March 2016. Previously, at Genentech, he served as Director of Collaboration Finance from June 2003 to September 2004, Director of Corporate Accounting and Reporting from September 2004 to May 2005, Assistant Controller and Senior Director, Corporate Finance from May 2005 to June 2006, Controller from June 2006 to November 2008, Chief Accounting Officer from April 2007 to November 2008 and Vice President, Controller and Chief Accounting Officer from November 2008 to March 2016. Prior to joining Genentech, he held various officer positions at HopeLink Corporation, a healthcare information technology company, from 2000 to 2003 and was a member of the Board of Directors of HopeLink from 2002 to 2003. Mr. Andreatta worked for KPMG from 1983 to 2000, including service as an audit partner from 1995 to 2000. He earned a Bachelor of Science degree in accounting from Santa Clara University.

Steven James

Mr. Steven P. James is Independent Director of the Company April 2016. From July 2014 to present, Mr. James has been an independent director at several biotechnology companies and served as acting or interim Chief Executive Officer at Antiva Biosciences (previously Hera Therapeutics) and Pionyr Immunotherapeutics (previously Precision Immune). Mr. James served as President and Chief Executive Officer of Labrys Biologics, from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014. He was President and Chief Executive Officer of KAI Pharmaceuticals, from October 2004 until its acquisition by Amgen in July 2012. He was Senior Vice President, Commercial Operations, at Exelixis, from 2003 until 2004. Previously he held senior business roles at Sunesis Pharmaceuticals and Isis Pharmaceuticals. He began his career in new product planning at Eli Lilly and Company. Mr. James was also a member of the board of directors of Cascadian Therapeutics and Ocera Therapeutics, and is currently a director of Antiva Biosciences, Chrono Therapeutics and Pionyr Immunotherapeutics, where he has been President and Chief Executive Officer since January 2016. Mr. James earned a Bachelor of Arts degree in biology from Brown University and a Masters in Management degree from the Kellogg Graduate School of Management at Northwestern University.

John McKearn

Dr. John P. McKearn Ph.D. is Independent Director of Allakos Inc since December 2012. Dr. McKearn joined RiverVest Venture Partners, a venture capital firm, in April 2008 as a Venture Partner and has been a Managing Director since April 2011. Prior to joining RiverVest, Dr. McKearn was the Chief Executive Officer of Kalypsys, a biopharmaceutical company, from 2005 to December 2006, its President from 2004 to December 2006 and its Chief Scientific Officer from 2003 to 2005. From 2000 to June 2009, Dr. McKearn served on the board of IDM Pharma (acquired by Takeda), a biotechnology company. He also previously served on the board of directors of Epimmune, Keel Pharmaceuticals, ZS Pharma, Otonomy and Lumena Pharmaceuticals. From 1987 to 2003, Dr. McKearn worked as a scientist with G.D. Searle & Company, which merged into Pharmacia Corporation in 2000, serving as the head of discovery research from 1997 to 2003. Before that, he was a senior scientist at E.I. DuPont de Nemours and Company, a member of the Basel Institute for Immunology in Basel, Switzerland and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis. Dr. McKearn holds a Bachelor’s degree in biology from Northern Illinois University and a Ph.D. in immunology from the University of Chicago.

Paul Walker

Mr. Paul Edward Walker is an Independent Director of the Company. Mr. Walker has been a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since April 2008, where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008, Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, private-investment-in-public-equity and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000, Mr. Walker served as a portfolio manager at Franklin Resources, a global investment management organization known as Franklin Templeton Investments. Mr. Walker previously served as a member of the board of directors of TESARO, currently serves as a member of the board of directors of TRACON Pharmaceuticals, is a board observer of Sunesis Pharmaceuticals and manages a number of NEA’s other late-stage and public investments. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the designation of Chartered Financial Analyst.